Personalis Ownership | Who Owns Personalis?
Personalis Ownership Summary
Personalis is owned by 68.28% institutional investors, 31.36% insiders, and 0.37% retail investors. Merck is the largest institutional shareholder, holding 15.87% of PSNL shares. ARK Genomic Revolution is the top mutual fund, with 7.84% of its assets in Personalis shares.
PSNL Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Personalis | 68.28% | 31.36% | 0.37% |
Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
Industry | Diagnostics & Research Stocks | 57.60% | 10.69% | 31.72% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Merck | 14.04M | 15.87% | $92.13M |
Ark investment management | 7.11M | 8.03% | $46.63M |
Blackrock | 3.29M | 6.50% | $3.85M |
Blackrock funding, inc. /de | 5.20M | 5.88% | $34.14M |
Aigh capital management | 3.72M | 4.21% | $24.43M |
Vanguard group | 1.73M | 2.84% | $10.03M |
Millennium management | 1.32M | 2.16% | $7.61M |
Abrdn | 1.76M | 1.99% | $11.54M |
Blue water life science advisors, lp | 1.68M | 1.89% | $11.00M |
Renaissance | 920.87K | 1.51% | $5.32M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Merck | 14.04M | 42.73% | $92.13M |
Aigh capital management | 3.72M | 10.99% | $24.43M |
Blue water life science advisors, lp | 1.68M | 8.70% | $11.00M |
Perkins capital management | 252.50K | 1.67% | $1.66M |
Wellington shields | 292.49K | 0.54% | $1.92M |
Bruce | 253.00K | 0.54% | $1.66M |
Wellington shields capital management | 426.33K | 0.47% | $2.80M |
Ark investment management | 7.11M | 0.34% | $46.63M |
Green alpha advisors | 31.84K | 0.20% | $208.86K |
Kennedy capital management | 653.38K | 0.10% | $4.29M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Blackrock funding, inc. /de | 5.20M | 0.00% | 2.21M |
T. rowe price investment management | 1.26M | 0.01% | 1.26M |
Susquehanna group, llp | 873.10K | 0.00% | 718.34K |
Blue water life science advisors, lp | 1.68M | 8.70% | 500.90K |
Exoduspoint capital management, lp | 437.37K | 0.03% | 403.20K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Millennium management | 1.32M | 0.00% | -1.12M |
Marshall wace, llp | - | - | -696.29K |
Qube research | 19.24K | 0.00% | -383.04K |
Acadian asset management | 39.16K | 0.00% | -271.36K |
Jane street group | - | - | -247.01K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
T. rowe price investment management | 1.26M | 0.01% | 1.26M | $8.29M |
Polar asset management partners | 71.70K | 0.01% | 71.70K | $470.35K |
Mach-1 financial group | 48.82K | 0.09% | 48.82K | $320.27K |
Intech investment management | 26.32K | 0.00% | 26.32K | $172.64K |
Mariner | 16.39K | 0.00% | 16.39K | $107.49K |
Sold Out
Holder | Change |
---|---|
Nelson, van denburg & campbell wealth management group | -100.00 |
Redwood wealth management group | -100.00 |
Org partners | -100.00 |
Creative planning | -157.00 |
Signaturefd | -257.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Jun 30, 2025 | 107 | 0.94% | 60,437,524 | 85.26% | 68 | 4.91% | 69 | 13.11% | 25 | -10.71% |
Mar 31, 2025 | 108 | -0.92% | 54,828,815 | 6.28% | 62 | 0.88% | 62 | 12.73% | 28 | -20.00% |
Dec 31, 2024 | 59 | -32.18% | 23,614,794 | -19.46% | 38 | 1.68% | 25 | -37.50% | 22 | -24.14% |
Sep 30, 2024 | 87 | 24.29% | 29,319,370 | 33.53% | 48 | 2.56% | 40 | 110.53% | 29 | - |
Jun 30, 2024 | 70 | -4.11% | 21,956,674 | -1.41% | 43 | 2.03% | 19 | -44.12% | 29 | 20.83% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
ARK Genomic Revolution | 6.95M | 7.84% | -118.85K |
ARK Genomic Revolution ETF | 6.89M | 7.80% | -41.30K |
Vanguard Total Stock Mkt Idx Inv | 1.74M | 1.97% | -38.65K |
Nikko Gbl All Biological Genome Eq MF | 932.69K | 1.41% | -150.91K |
Vanguard US Total Market Shares ETF | 1.21M | 1.37% | - |
iShares Russell 2000 ETF | 1.21M | 1.37% | -23.00K |
abrdn Healthcare Investors | 973.60K | 1.10% | 93.80K |
abrdn Life Sciences Investors | 917.02K | 1.03% | 37.32K |
T. Rowe Price Small-Cap Value | 765.80K | 0.87% | 765.80K |
Vanguard Institutional Extnd Mkt Idx Tr | 672.09K | 0.76% | -294.03K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jul 28, 2025 | Chen Richard | CHIEF MEDICAL OFFICER AND EVP | Sell | $2.97K |
Jul 28, 2025 | Tachibana Aaron | CFO AND COO | Sell | $4.21K |
May 16, 2025 | Tachibana Aaron | CFO AND COO | Sell | $6.39K |
May 16, 2025 | Moore Stephen Michael | SVP and Chief Legal Officer | Sell | $8.29K |
May 16, 2025 | Chen Richard | CHIEF MEDICAL OFFICER AND EVP | Sell | $4.50K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q3 | - | 2 |
2025 Q2 | - | 3 |
2025 Q1 | - | 2 |
2024 Q4 | - | 7 |
2024 Q3 | 1 | 2 |
PSNL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools